<DOC>
	<DOCNO>NCT00529230</DOCNO>
	<brief_summary>Primary Objective : 1 . To determine prevalence secondary hypogonadism male patient chronic opioid therapy cancer-related pain syndrome . Secondary Objective : 1 . To determine degree sexual dysfunction , fatigue , depression prevalent male patient chronic opioid therapy cancer-related pain syndrome .</brief_summary>
	<brief_title>Prevalence Secondary Hypogonadism Male Patients Chronic Opioid Therapy Cancer-Related Pain Syndromes</brief_title>
	<detailed_description>Studies show non-cancer patient take opioid pain medication long period time decrease libido decrease sexual function . Individuals may ask take part study even take opioid pain medication last twelve month . These individual would also enrol learn long-term treatment cancer-related pain opioid medication result decrease sex hormone , decrease sex drive , increase fatigue depression . Participants study ask complete set question sexual function , physical symptom , psychological symptom fatigue depression . It take 25 minute complete questionnaire . Participants blood drawn ( 2 teaspoon blood ) test sex hormone level . Participants identify low sex hormone level ( hypogonadism ) refer endocrinologist standard hormone replacement therapy . This one-time evaluation , follow-up visit questionnaire require . This investigational study . A total 108 individual take part study . All enrol UTMDACC .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<criteria>1 . Chronic pain great one year . 2 . Male . 3 . Cancer status must stable remission . For study , `` stable disease '' define identifiable disease local metastatic site show progression previous 3 month cancer treatment ³ 3 month . 4 . Patients must chronic opioid therapy continuous basis precede twelve month Morphine Equivalent Daily Dose ( MEDD ) ³ 200 . 5 . Age &gt; /= 18 . The questionnaire use study validate adult population . In addition , questionnaires contain question sensitive nature appropriate pediatric population . 6 . Patients must able understand sign consent form . 1 . Patient refuse participate study determine incapable complete research . 2 . Patients preexist hypopituitarism . Causes include certain tumor ( pituitary adenoma , hypothalamic tumor ) , inflammatory disease ( granulomatous disease ) , vascular disease ( postpartum necrosis , carotid aneurysm ) , traumatic/destructive event ( prior surgery , trauma , radiation ) , developmental anomaly , infiltration . 3 . Patients tare take drug may affect hypothalamicpituitarygonadal axis .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Chronic Opioid Therapy</keyword>
	<keyword>Secondary Hypogonadism</keyword>
	<keyword>Cancer-Related Pain Syndromes</keyword>
	<keyword>Questionnaire</keyword>
</DOC>